Hims & Hers Stock Navigates Credibility Test Ahead of Key FDA Decision

Shares of Hims & Hers Health (HIMS) are at a crossroads as the telehealth company's rapid growth narrative collides with significant questions about its profitability and business model. With a crucial U.S. Food and Drug Administration (FDA) advisory committee meeting scheduled for July 23–24, investors are closely watching for a catalyst that could either validate the company's high valuation or reinforce bearish concerns.

The Growth Story

The bull case for Hims & Hers is centered on its formidable revenue expansion. The company's revenue surged from $527 million in fiscal 2022 to $2.35 billion in fiscal 2025, with consensus estimates projecting further growth to $3.44 billion by fiscal 2027, according to the source material.

The April 1, 2026, launch of its oral Wegovy offering provided an initial boost, prompting analysts at Barclays and Canaccord to raise their price targets to $39 and $40, respectively. Furthermore, card data from June suggests the company is on track to beat second-quarter revenue estimates and raise its guidance, according to an analysis by Truist.

Profitability and Retention Headwinds

Despite the top-line growth, the company's profitability has come under intense scrutiny. Fiscal 2026 earnings per share (EPS) estimates have been revised downward by a dramatic 77% over the past year. The company posted a significant Q1 2026 EPS miss of -$0.40 against an expected +$0.01, sending the stock down over 11% on the day of the report.

Ad

Key concerns for bears include:

• Valuation: The stock trades at a high multiple of 104x EV/EBITDA, which analysts note is a price for perfection. InvestingPro’s Fair Value model suggests a potential 19% downside to $26.53.
• Wegovy Churn: Bank of America has flagged a potential retention issue, as customers face a price hike from $39 in their first month to $149 in their second. The bank noted that a competitor, Ro, is already seeing declining new customers after a similar launch.
• Analyst Sentiment: Six analysts have recently revised EPS estimates downward, and the upcoming departure of the company's Chief Accounting Officer adds a layer of governance uncertainty.

FDA Peptide Decision Looms

The most significant near-term event is the FDA’s Pharmacy Compounding Advisory Committee meeting on July 23–24. The committee will consider approving seven peptides for compounding, which bulls believe could open a major new revenue stream for Hims & Hers.

However, even a favorable outcome may not provide an immediate financial boost. Analysts at Truist have noted that meaningful revenue from peptides is unlikely to materialize before 2028. The meeting's result is expected to heavily influence investor sentiment, either by adding a new growth driver or by confirming that the company's path to sustained profitability remains challenging.